ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 158 filers reported holding ALLOGENE THERAPEUTICS INC in Q1 2024. The put-call ratio across all filers is 0.47 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2023 | $264,966 | -61.0% | 82,544 | -61.5% | 0.00% | -60.0% |
Q3 2023 | $678,836 | +586.3% | 214,144 | +975.9% | 0.01% | +400.0% |
Q2 2023 | $98,918 | -95.8% | 19,903 | -95.8% | 0.00% | -92.9% |
Q1 2023 | $2,334,851 | +28.4% | 472,642 | +63.5% | 0.01% | +27.3% |
Q4 2022 | $1,817,804 | -70.9% | 288,999 | -50.1% | 0.01% | -68.6% |
Q3 2022 | $6,256,000 | +99.7% | 579,245 | +110.8% | 0.04% | +84.2% |
Q2 2022 | $3,133,000 | +66.9% | 274,800 | +33.4% | 0.02% | +18.8% |
Q1 2022 | $1,877,000 | -10.7% | 206,033 | +46.3% | 0.02% | -20.0% |
Q4 2021 | $2,101,000 | -35.4% | 140,790 | +13.0% | 0.02% | -45.9% |
Q2 2021 | $3,250,000 | +227.6% | 124,598 | +343.4% | 0.04% | +184.6% |
Q1 2021 | $992,000 | -65.0% | 28,101 | -75.0% | 0.01% | -66.7% |
Q4 2020 | $2,835,000 | +454.8% | 112,321 | +840.5% | 0.04% | +333.3% |
Q2 2020 | $511,000 | +87.9% | 11,943 | -14.8% | 0.01% | +28.6% |
Q1 2020 | $272,000 | -73.0% | 14,012 | -63.9% | 0.01% | -61.1% |
Q4 2019 | $1,009,000 | – | 38,833 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vida Ventures Advisors, LLC | 1,798,163 | $4,189,720 | 4.58% |
SUPERSTRING CAPITAL MANAGEMENT LP | 689,912 | $1,607,495 | 2.03% |
Lynx1 Capital Management LP | 2,228,295 | $5,191,927 | 1.87% |
Wildcat Capital Management, LLC | 2,920,787 | $6,805,434 | 1.66% |
TPG GP A, LLC | 18,716,306 | $43,608,993 | 1.00% |
Boxer Capital, LLC | 3,850,000 | $8,970,500 | 0.47% |
Vestal Point Capital, LP | 2,200,000 | $5,126,000 | 0.38% |
DAFNA Capital Management LLC | 605,100 | $1,409,883 | 0.34% |
Frazier Life Sciences Management, L.P. | 2,867,750 | $6,681,858 | 0.31% |
Coastal Bridge Advisors, LLC | 406,847 | $947,954 | 0.24% |